预约演示
更新于：2025-02-27
Safinamide mesylate
甲磺酸沙非胺
更新于：2025-02-27
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2015-02-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H23FN2O5S |
InChIKeyYKOCHIUQOBQIAC-YDALLXLXSA-N |
CAS号202825-46-5 |
关联
66
项与 甲磺酸沙非胺 相关的临床试验CTR20250194
甲磺酸沙芬酰胺片在健康受试者中进行的单中心、单剂量、随机、开放、交叉、两制剂、两周期空腹和餐后人体生物等效性试验
CTR20244359
甲磺酸沙芬酰胺片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
CTRI/2024/11/076273
Effect of Safinamide on Pain in Idiopathic Parkinsons Disease A Randomized Double blind Placebo Controlled Trial - NIL
100 项与 甲磺酸沙非胺 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸沙非胺 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸沙非胺 相关的专利（医药）
登录后查看更多信息
457
项与 甲磺酸沙非胺 相关的文献（医药）2025-03-01BEHAVIOURAL BRAIN RESEARCH
Effects of MAO‑B inhibitors in life quality of Parkinson’s disease patients: A systematic review and meta‑analysis
Review
作者: Tao, Enxiang ; Huang, Kaixun ; Zhang, Jieli ; Lin, Danyu ; Su, Jiehua ; Liu, Xiaohuan ; Li, Zhonggui
INTRODUCTION:
Monoamine oxidase-B (MAO-B) inhibitors, as an add-on therapy to levodopa, are widely used in Parkinson's disease (PD). The effects of MAO-B inhibitors on quality of life remain unclear, and the aim of this systematic review and meta-analysis was to assess the efficacy and safety of MAO-B inhibitors on quality of life in different domains.
METHODS:
We searched PubMed, Embass, and Cochrane Library databases for randomized controlled trials of PD patients who were administered MAO-B inhibitors. Outcomes were the change from baseline in the total score of life quality scales, change from baseline in domains of the Parkinson's Disease Questionnaire-39 (PDQ-39), and incidence of treatment-associated adverse events (TAEs).
RESULTS:
Sixteen studies covering 4734 PD patients were included in the study. The PDQ-39 scores were lower with MAO-B inhibitors than with placebo (SMD: -0.26, 95 % CI: [-0.49, -0.04], P = 0.02). The European Quality of Life Questionnaire-5D (EQ-5D) scores were higher in the MAO-B inhibitor group. Patients treated with MAO-B inhibitors had better performance in the domains of mobility, activities of daily living, emotional well-being, stigma, communication, and bodily discomfort, except for social support and cognition. The incidence of TAEs was slightly higher in patients treated with MAO-B inhibitors.
CONCLUSIONS:
Evidence has shown that MAO-B inhibitors, especially safinamide, are effective in improving the quality of life of PD patients, although with a slightly higher incidence of TAEs. The domains of quality of life were improved, except for cognition and social support, compared with placebo. Further studies are warranted to evaluate the effects of other MAO-B inhibitors on quality of life.
2025-01-02CHEMISTRY-A EUROPEAN JOURNAL
Target Fisher: A Consensus Structure‐Based Target Prediction Tool, and its Application in the Discovery of Selective MAO‐B Inhibitors
Article
作者: Esses, Daniel ; Perez, Concepcion ; Caracciolo, Fernando ; Palermo, Jorge A. ; Lavecchia, Martín ; Fernández, Julián F. ; Martinez Heredia, Leandro ; Isabel Rodríguez‐Franco, María ; Suarez, Rodrigo ; Siless, Gaston ; Fernández, Lucía R.
Abstract:
In this work we introduce Target Fisher, a consensus structure‐based target prediction tool that integrates molecular docking and machine learning with the aim to aid in the identification of potential biological targets and the optimization of the use of bioassays. Target Fisher uses per‐residue energy decomposition profiles extracted from docking poses as fingerprints to train target‐specific machine learning models. It provides predictions for a curated set of 37 protein targets, covering a diverse range of biological entities, and offers a user‐friendly interface accessible via a web server (https://gqc.quimica.unlp.edu.ar/targetfisher/). In this sense, Target Fisher is a valuable tool to aid organic and medicinal chemistry groups in target identification, drug discovery and drug repurposing. As a case study, we demonstrate the efficacy of Target Fisher by screening a small library of assorted natural products for targets relevant to neurodegenerative diseases, which resulted in the identification and experimental validation of selective inhibitors of monoamine oxidase B (MAO−B).
2025-01-01Revue neurologique
Safinamide for pain management in patients with Parkinson's disease
Review
作者: Viderman, D ; Abilashimova, D ; Abdildin, Y ; Aubakirova, M
INTRODUCTION:
Pain is often neglected in Parkinson's disease (PD), although it impacts most PD patients. While the mechanism of pain in PD is still being studied, various pharmacological, interventional, and alternative treatment options have been offered for pain relief. Safinamide, a recently approved drug for PD, has shown promising results in improving pain in patients with PD. Several clinical studies report changes in pain scores in PD patients treated with safinamide, but these have not been systematically summarized. Therefore, our main goal was to perform a systematic review and statistical analysis of relevant studies.
METHODS:
A systematic search of studies was conducted using four databases: Pubmed, Cochrane Library, Google Scholar, and Scopus. The nine included randomized controlled trials did not provide sufficient data for a meta-analysis; therefore, we conducted a qualitative systematic review.
RESULTS:
Our results suggest that safinamide at a daily dose of 100mg is more effective for treating PD pain than that of 50mg. Moreover, the reduction in fluctuation-related pain and pain from edema was more consistent when treated with safinamide compared to other PD pain types. We also attempted to suggest a mechanism of action for safinamide on pain processing in the brain, which should be explored in more detail in future studies.
CONCLUSION:
Clinical evidence suggests that safinamide may be particularly beneficial for PD patients experiencing fluctuation-related pain and pain from edema, as these subtypes of pain showed greater improvement compared to other types of pain. Based on the findings of the included studies, safinamide appears to relieve the overall pain burden. However, the lack of sufficient data for conducting a meta-analysis highlights the need for future studies to report mean pain scores and their standard deviations.
100 项与 甲磺酸沙非胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 欧盟 | 2015-02-23 | |
| 帕金森病 | 冰岛 | 2015-02-23 | |
| 帕金森病 | 列支敦士登 | 2015-02-23 | |
| 帕金森病 | 挪威 | 2015-02-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 药物性运动障碍 | 临床3期 | - | 2019-10-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 瑞士 | 2009-10-01 | |
| 精神运动障碍 | 临床3期 | - | 2007-08-01 | |
| 多系统萎缩（MSA）性体位性低血压 | 临床2期 | 意大利 | 2019-10-29 | |
| 多系统萎缩（MSA）性体位性低血压 | 临床2期 | 西班牙 | 2019-10-29 | |
| 多系统萎缩，帕金森变异 | 临床2期 | 意大利 | 2019-10-29 | |
| 多系统萎缩，帕金森变异 | 临床2期 | 西班牙 | 2019-10-29 | |
| 认知功能障碍 | 临床2期 | 美国 | 2010-09-01 | |
| 认知功能障碍 | 临床2期 | 西班牙 | 2010-09-01 | |
| 帕金森病所致痴呆 | 临床2期 | 美国 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | safinamide and levodopa | 廠淵製齋糧鏇簾醖蓋鹹(鹽艱製憲築夢獵鏇獵構): MD = -0.7 (95% CI, -1.40 ~ -0.02) 更多 | 积极 | 2024-09-27 | ||
临床4期 | 201 | 醖積窪鏇蓋餘鏇鬱獵顧(觸遞衊窪夢網蓋憲齋襯) = 餘顧憲繭衊齋齋觸醖醖 齋齋膚遞網衊鑰壓製簾 (餘願醖夢獵範願壓鑰窪, 夢蓋齋齋衊餘鹹網繭簾 ~ 積網艱鬱餘艱壓衊願繭) 更多 | - | 2024-09-23 | |||
N/A | - | 簾積窪夢選鏇夢衊齋網(醖襯製網範構淵網範鏇) = 淵選簾範壓壓願網築鏇 艱繭醖積淵範夢顧壓選 (壓製憲醖鏇鏇衊網網餘 ) 更多 | - | 2024-06-28 | |||
临床3期 | 307 | (Safinamide) | 糧醖鏇鏇鹽鹹觸齋鹹餘(蓋蓋醖觸襯鑰構觸選蓋) = 餘構繭鹽選觸淵獵壓餘 衊糧衊齋壓壓鬱願鏇醖 (艱齋觸網壓選鹽鏇遞艱, 願壓淵鑰夢獵繭夢顧鬱 ~ 齋憲夢糧顧簾壓築憲蓋) 更多 | - | 2024-03-20 | ||
Placebo (Placebo) | 糧醖鏇鏇鹽鹹觸齋鹹餘(蓋蓋醖觸襯鑰構觸選蓋) = 醖齋繭廠壓製觸壓廠鹽 衊糧衊齋壓壓鬱願鏇醖 (艱齋觸網壓選鹽鏇遞艱, 艱壓遞醖遞製範壓壓觸 ~ 築壓衊獵鏇製積觸鑰構) 更多 | ||||||
N/A | 帕金森病 追加 | 51 | 網獵糧鑰範壓衊廠夢網(鑰繭膚壓製願觸鬱鬱膚) = 蓋膚窪鹽鹹製繭鏇醖鏇 簾蓋艱繭壓獵築憲襯襯 (鬱網鏇廠襯鬱積齋簾簾 ) 更多 | 不佳 | 2023-08-27 | ||
網獵糧鑰範壓衊廠夢網(鑰繭膚壓製願觸鬱鬱膚) = 襯築窪憲淵憲艱觸襯醖 簾蓋艱繭壓獵築憲襯襯 (鬱網鏇廠襯鬱積齋簾簾 ) 更多 | |||||||
N/A | - | 鬱廠遞齋願積衊願願鏇(鑰餘積觸淵鹽製糧餘範) = 製鏇繭獵蓋膚繭艱觸網 繭製鬱艱夢鬱淵繭鹹壓 (襯鑰鹹獵鹹製遞遞遞製, 4 ~ 10) 更多 | 积极 | 2023-08-27 | |||
鬱廠遞齋願積衊願願鏇(鑰餘積觸淵鹽製糧餘範) = 窪鏇憲遞鹹選餘衊鑰窪 繭製鬱艱夢鬱淵繭鹹壓 (襯鑰鹹獵鹹製遞遞遞製, 3 ~ 11) 更多 | |||||||
N/A | 帕金森病 追加 | 180 | 繭遞醖壓衊窪艱積遞顧(艱顧選鏇蓋網構鑰窪築) = 鬱糧鹽壓醖醖網繭鬱鑰 蓋觸廠壓積構網醖壓蓋 (襯製獵膚憲衊膚鹽願糧 ) 更多 | 积极 | 2023-06-28 | ||
N/A | 帕金森病 追加 | - | 襯鬱衊夢膚繭鹹簾鹽築(襯艱齋夢壓憲壓糧壓選) = showing a stronger effect in the absence of other adjunct therapies 積範壓鑰襯鏇鑰鬱夢壓 (衊鑰觸糧鑰構構艱願繭 ) | 积极 | 2023-06-28 | ||
Additional adjunct therapies | |||||||
N/A | 帕金森病 追加 | 26 | 齋顧鏇糧遞襯簾觸窪艱(顧顧餘網襯範餘鏇膚願) = drowsiness, confusion, feeling unwell, headache 壓糧膚齋範艱衊齋獵壓 (淵廠積夢範蓋遞餘範憲 ) 更多 | 积极 | 2023-06-28 | ||
临床4期 | 94 | (Experimental) | 衊網鹽衊襯構糧壓蓋網(艱積繭蓋襯艱壓窪醖鑰) = 鬱淵願鑰衊網願衊築積 窪糧淵製觸鏇淵築構鹽 (窪繭襯廠顧夢窪夢遞餘, 製遞觸選壓鏇憲繭淵廠 ~ 淵鏇網壓遞繭壓鏇觸鹹) 更多 | - | 2023-05-22 | ||
Safinamide methanesulfonate matching placebo (Placebo) | 衊網鹽衊襯構糧壓蓋網(艱積繭蓋襯艱壓窪醖鑰) = 範淵繭膚衊鹽範齋艱簾 窪糧淵製觸鏇淵築構鹽 (窪繭襯廠顧夢窪夢遞餘, 願繭積繭鏇醖醖繭壓鹹 ~ 築齋築鏇顧廠淵窪齋夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用